ADHD drug developer Cingulate's Q4 net loss misses analyst expectations as G&A costs rise

Overview

• US biopharma firm's Q4 net loss widened and missed analyst expectations

• R&D expenses fell while G&A costs rose due to pre-commercialization activities

• Company closed $12 mln PIPE financing and advanced lead ADHD drug candidate to FDA review in February

Outlook

• Company expects current cash to cover capital needs into late fourth qtr 2026

Result Drivers

• HIGHER G&A COSTS - Co said increased general and administrative expenses, mainly from pre-commercialization activities, personnel, and legal fees, drove higher net loss

• LOWER R&D EXPENSES - Co said research and development expenses fell in Q4 due to decreased clinical operations costs

Company press release: ID:nGNX90Dvd4

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Cingulate Inc is $25.50, about 118.7% above its March 17 closing price of $11.66

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.